Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dexmedetomidine for Preventing Postoperative Delirium and a Risk Prediction Nomogram in Older Adults Undergoing Gastrointestinal Surgery
Sponsor: Hanoi Medical University
Summary
Postoperative delirium (POD) is a common and serious complication in older adults after major gastrointestinal surgery and is associated with longer hospital stay, long-term cognitive decline and higher mortality. Dexmedetomidine, a highly selective alpha-2 adrenergic agonist with sedative, anti-inflammatory and opioid-sparing effects, may reduce POD, but evidence in older patients undergoing gastrointestinal surgery remains inconsistent, and tools to identify which patients are at highest risk are lacking. The goal of this randomized, double-blind, placebo-controlled trial is to learn whether intraoperative and early postoperative dexmedetomidine prevents POD in patients aged 60 years or older undergoing elective gastrointestinal surgery under general anesthesia, and to develop a risk prediction nomogram for POD in this population. The main questions it aims to answer are: 1. Does dexmedetomidine lower the incidence of POD within 5 days after surgery compared with placebo, and is it safe? 2. How accurately can a prediction model (nomogram) built from preoperative and intraoperative factors estimate each patient's risk of POD? Researchers will also examine how dexmedetomidine changes postoperative inflammatory and stress markers (IL-6, cortisol, CRP, NLR, SII) and their association with POD, and whether the benefit of dexmedetomidine differs across baseline-risk strata. Participants will be randomly assigned to dexmedetomidine or placebo (0.9% saline). The blinded infusion starts 15 minutes before induction of anesthesia (dexmedetomidine 0.5 mcg/kg over 15 minutes, then 0.5 mcg/kg/h until 2 hours after surgery, or the same volume and rate of saline). Delirium will be assessed three times daily with the 3D-CAM (or CAM-ICU for patients who cannot be interviewed) from the end of surgery until postoperative day 5 or hospital discharge.
Official title: Efficacy of Dexmedetomidine in Preventing Postoperative Delirium and a Risk Prediction Nomogram in Geriatric Patients Undergoing Gastrointestinal Surgery: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Trial
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
INTERVENTIONAL
Enrollment
630
Start Date
2026-12-01
Completion Date
2028-04-30
Last Updated
2026-11-19
Healthy Volunteers
No
Interventions
Dexmedetomidine
Selective alpha-2 adrenergic agonist. Dexmedetomidine Invagen 200 mcg/2 mL (SIA Pharmidea, Latvia; Vietnamese marketing authorization 475114010723). Dose reduced to 0.3 mcg/kg/h for bradycardia with hypotension; stopped for HR \< 40/min, new 2nd-3rd degree AV block, refractory hypotension, or RASS \<= -3 / SpO2 \< 90% after extubation.
Placebo
Identical-appearing 0.9% sodium chloride solution administered with the same syringe, label, volume, rate and duration.
Locations (1)
Hanoi Medical University Hospital
Hanoi, Vietnam